US pharma major AbbVie recently announced top-line results from one of two parallel studies of the pivotal Phase III UP-AA ...

The cancer immunotherapy market is bracing for its next growth phase as bispecific T-cell engagers gain momentum, according ...

UK pharma major GSK (LSE: GSK) today announced that, in connection with the mRNA patent settlement reached between CureVac ...

French vaccines developer Valneva announced that the US Food and Drug Administration (FDA) has removed its recommended pause ...

German family-owned pharma major Boehringer Ingelheim and New York-based Click Therapeutics today announced that the pivotal ...

Danish biotech Genmab (Nasdaq: GMAB) and US partner AbbVie (NYSE: ABBV) have reported a decisive win in a Phase III study of ...

Danish biotech Genmab (Nasdaq: GMAB) posted second-quarter revenue of $925 million, up 19% from a year earlier, driven by ...

US clinical-stage biotech Keros Therapeutics has announced a strategic realignment designed to reallocate resources towards ...

Shares in Gilead Sciences were a massive 9% higher in Friday’s early trading after the US biotech major lifted its full-year financial guidance.

India’s pharmaceutical sector continues to assert its dominance on the global stage, driven by a surge in generic drug launches that are reshaping access to affordable healthcare. A flurry of filings ...

The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Chiesi’s idebenone within ...

Eli Lilly (NYSE: LLY) posted a 38% jump in revenue to $15.6 billion in the second quarter of 2025, driven by surging demand ...